Olaparib in Recurrent IDH-mutant Glioma
NCT03561870
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
35
Enrollment
OTHER
Sponsor class
Conditions
Recurrent IDH
Mutant High Grade Glioma
Interventions
DRUG:
Olaparib 150 MG
Sponsor
Hospices Civils de Lyon